<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02049164</url>
  </required_header>
  <id_info>
    <org_study_id>AR08.100</org_study_id>
    <nct_id>NCT02049164</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Forced Titration, Dose-ranging Study of AR08 in the Treatment of Vasomotor Symptoms (VMS) in Menopausal Females: A Proof-of-Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbor Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbor Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effective dose or dose range of AR08 in the
      treatment of VMS in menopausal females.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopping criteria met with regards to vital sign measurements post dose.
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from Baseline in the frequency and severity of moderate to severe hot flashes</measure>
    <time_frame>Weeks 4 and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression - Improvement (PGI-I)</measure>
    <time_frame>Weeks 4, 8, and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Vasomotor Symptoms (VMS)</condition>
  <arm_group>
    <arm_group_label>AR08 0.5 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AR08 QD oral dosing for 14 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AR08 1.0 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AR08 QD oral dosing for 14 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AR08 2.0 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AR08 QD oral dosing for 14 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo QD oral dosing for 14 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR08</intervention_name>
    <arm_group_label>AR08 0.5 mg/day</arm_group_label>
    <arm_group_label>AR08 1.0 mg/day</arm_group_label>
    <arm_group_label>AR08 2.0 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Generally healthy female &gt; 40 years of age with a body mass index (BMI) â‰¤ 40;

          2. Has undergone menopause defined as any of the following:

             At least 12 months of spontaneous amenorrhea; or At least 6 months of spontaneous
             amenorrhea with serum follicle-stimulating hormone (FSH) levels &gt; 40 mIU/mL; or At
             least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy);

          3. Experience a minimum of 7 moderate to severe hot flushes per day or 50 moderate to
             severe hot flushes per week

        Exclusion Criteria:

          1. Resting systolic blood pressure (SBP) &lt;110 mmHg, resting diastolic blood pressure
             (DBP) &lt;50 mm Hg, or a resting heart rate (HR) &lt;60 beats per minute while awake;

          2. Subjects with pre-existing orthostatic hypotension at Screening;

          3. Use of oral estrogen-, progestin-, androgen-, or selective estrogen receptor modifier
             (SERM) -containing drug products within 8 weeks prior to Screening; use of transdermal
             hormone products within 8 weeks prior to Screening; use of vaginal hormone products
             (rings, creams, gels) within 4 weeks prior to Screening; use of intrauterine
             progestins within 8 weeks prior to Screening; use of progestin implants or estrogen
             injectables within 3 months prior to Screening; use of estrogen pellet or progestin
             injectables within 6 months prior to Screening;

          4. History of daily usage (at least 28 days/month) of either of the following during the
             month prior to initiation of Screening: Antihypertensives or Prophylactic antimigraine
             medications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>41 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Genesis Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blue Skies Center for Women</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altus Research</name>
      <address>
        <city>Lakeworth</city>
        <state>Florida</state>
        <zip>99461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OB-GYN Associates of Mid-Florida, P.A.</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Trials, LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cypress Medical Research Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrence OB/Gyn Associates</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawthorne Medical Research, Inc.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Philadelphia, LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Medical Research, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TMC Life Research, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tidewater Physicians for Women</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Womens: Health, Research, Gynecology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2014</study_first_submitted>
  <study_first_submitted_qc>January 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2014</study_first_posted>
  <disposition_first_submitted>June 5, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>June 5, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 3, 2015</disposition_first_posted>
  <last_update_submitted>November 10, 2015</last_update_submitted>
  <last_update_submitted_qc>November 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AR08, Vasomotor Symptoms</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

